• Japan
  • 19 June 2012
  • Opinion
  • By Erin Brady

Top pharma deals in the last 5 years in APAC

Updated on 19 June 2012

6.In a bid that ultimately failed due to US competition authorities' intervention, Australia's biotherapeutics giant, CSL, attempted to acquire US-based plasma competitor Talecris for $3.1 billion in August 2008, to take advantage of synergies and improve its profitability in the US plasma market.

7.France-based Sanofi acquired the Australian consumer health business of Symbion in September 2008, gaining a substantial share of the vitamin supplements' markets in Australia and New Zealand.

8.Japan's Dainippon Sumitomo acquired US-based Sepracor for $2.6 billion in September 2009, gaining a presence in the US market.

9.Japan's Taisho Pharmaceuticals acquired Bristol-Myers Squibb's Indonesian operations and Asian over-the-counter business for $310 million in October 2009, expanding its reach in emerging Asian markets.

10.Swiss-based Novartis acquired Chinese pharmaceuticals and vaccines company Zhejiang Tianyuan Bio-Pharmaceutical for $125 millioin November 2009, in a move to increase its China operations.

1 3 5

Leave a Reply

Post Comment

Special Features

Survey Box

Chinese Bird Flu H5N7

Have Chinese scientists done the right thing by fusing human and avian flu strains to create new killer viruses?

Send this article by email

X